# A Mass Balance Study of [14C] SHR6508 in Chinese Hemodialysis Subjects With Secondary Hyperparathyroidism

> **NCT06877247** · PHASE1 · COMPLETED · sponsor: **Shanghai Hengrui Pharmaceutical Co., Ltd.** · enrollment: 5 (actual)

## Conditions studied

- Secondary Hyperparathyroidism

## Interventions

- **DRUG:** [14C] SHR6508 Injection

## Key facts

- **NCT ID:** NCT06877247
- **Lead sponsor:** Shanghai Hengrui Pharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2024-12-23
- **Primary completion:** 2025-04-04
- **Final completion:** 2025-10-11
- **Target enrollment:** 5 (ACTUAL)
- **Last updated:** 2026-03-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06877247

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06877247, "A Mass Balance Study of [14C] SHR6508 in Chinese Hemodialysis Subjects With Secondary Hyperparathyroidism". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT06877247. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*